Profile Image

Dr Erin Harvey

Research Assistant

School of Medicine and Public Health

Career Summary

Qualifications

  • PhD (Immunology & Microbiology), University of Newcastle
  • Bachelor of Biomedical Sciences, University of Newcastle
  • Bachelor of Biomedical Sciences (Hons), University of Newcastle

Keywords

  • testing

Fields of Research

Code Description Percentage
111299 Oncology and Carcinogenesis not elsewhere classified 100
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (8 outputs)

Year Citation Altmetrics Link
2019 Bulathsinhala L, Eleangovan N, Heaney LG, Menzies-Gow A, Gibson PG, Peters M, et al., 'Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study', Journal of Allergy and Clinical Immunology: In Practice, 7 578-588.e2 (2019) [C1]

© 2018 American Academy of Allergy, Asthma & Immunology Background: The lack of centralized data on severe asthma has resulted in a scarcity of information about the disease... [more]

© 2018 American Academy of Allergy, Asthma & Immunology Background: The lack of centralized data on severe asthma has resulted in a scarcity of information about the disease and its management. The development of a common data collection tool for the International Severe Asthma Registry (ISAR) will enable standardized data collection, subsequently enabling data interoperability. Objectives: To create a standardized list of variables for the first international registry for severe asthma via expert consensus. Methods: A modified Delphi process was used to reach consensus on a minimum set of variables to capture in ISAR: the core variables. The Delphi panel brought together 27 international experts in the field of severe asthma research. The process consisted of 3 iterative rounds. In each round, all Delphi panel members were issued an electronic ISAR Delphi workbook to complete and return to the ISAR Delphi administrator. Workbooks and result summaries were anonymously distributed by the Delphi administrator to all panel members at subsequent rounds. Finalization of the core variable list was facilitated by 2 face-to-face meetings. Results: Of the initial 747 selected variables, the Delphi panel reached a consensus on 95. The chosen variables will allow severe asthma to be assessed against patient demographics and medical history, patient-reported outcomes, diagnostic information, and clinical characteristics. Physician-reported outcomes such as nonadherence and information about treatment and management strategies will also be recorded. Conclusions: This is the first global attempt to generate an ISAR using a common set of core variables to ensure that data collected across all participating countries are standardized.

DOI 10.1016/j.jaip.2018.08.016
Citations Scopus - 5Web of Science - 5
Co-authors Peter Gibson
2019 Denton E, Hore-Lacy F, Radhakrishna N, Gilbert A, Tay T, Lee J, et al., 'Severe Asthma Global Evaluation (SAGE): An Electronic Platform for Severe Asthma.', J Allergy Clin Immunol Pract, 7 1440-1449 (2019)
DOI 10.1016/j.jaip.2019.02.042
Co-authors Peter Gibson
2019 McDonald VM, Hiles SA, Godbout K, Harvey ES, Marks GB, Hew M, et al., 'Treatable traits can be identified in a severe asthma registry and predict future exacerbations', Respirology, 24 37-47 (2019) [C1]

© 2018 Asian Pacific Society of Respirology Background and objective: A new taxonomic and management approach, termed treatable traits, has been proposed for airway diseases inclu... [more]

© 2018 Asian Pacific Society of Respirology Background and objective: A new taxonomic and management approach, termed treatable traits, has been proposed for airway diseases including severe asthma. This study examined whether treatable traits could be identified using registry data and whether particular treatable traits were associated with future exacerbation risk. Methods: The Australasian Severe Asthma Web-Based Database (SAWD) enrolled 434 participants with severe asthma and a comparison group of 102 participants with non-severe asthma. Published treatable traits were mapped to registry data fields and their prevalence was described. Participants were characterized at baseline and every 6 months for 24 months. Results: In SAWD, 24 treatable traits were identified in three domains: pulmonary, extrapulmonary and behavioural/risk factors. Patients with severe asthma expressed more pulmonary and extrapulmonary treatable traits than non-severe asthma. Allergic sensitization, upper-airway disease, airflow limitation, eosinophilic inflammation and frequent exacerbations were common in severe asthma. Ten traits predicted exacerbation risk; among the strongest were being prone to exacerbations, depression, inhaler device polypharmacy, vocal cord dysfunction and obstructive sleep apnoea. Conclusion: Treatable traits can be assessed using a severe asthma registry. In severe asthma, patients express more treatable traits than non-severe asthma. Traits may be associated with future asthma exacerbation risk demonstrating the clinical utility of assessing treatable traits.

DOI 10.1111/resp.13389
Citations Scopus - 8Web of Science - 7
Co-authors Peter Wark, Vanessa Mcdonald, Sarah Hiles, Peter Gibson
2018 Hiles SA, Harvey ES, McDonald VM, Peters M, Bardin P, Reynolds PN, Upham JW, 'Working while unwell: Workplace impairment in people with severe asthma', CLINICAL AND EXPERIMENTAL ALLERGY, 48 650-662 (2018)
DOI 10.1111/cea.13153
Citations Scopus - 5Web of Science - 5
Co-authors Vanessa Mcdonald, Peter Wark, Sarah Hiles, Peter Gibson
2017 Wang G, Wang F, Gibson PG, Guo M, Zhang WJ, Gao P, et al., 'Severe and uncontrolled asthma in China: A cross-sectional survey from the Australasian Severe Asthma Network', Journal of Thoracic Disease, 9 1333-1344 (2017) [C1]
DOI 10.21037/jtd.2017.04.74
Citations Scopus - 9Web of Science - 8
Co-authors Peter Gibson
2011 Au GG, Beagley LG, Haley ES, Barry RD, Shafren DR, 'Oncolysis of malignant human melanoma tumors by Coxsackieviruses A13, A15 and A18', Virology Journal, 8 1-6 (2011) [C1]
DOI 10.1186/1743-422x-8-22
Citations Scopus - 17Web of Science - 18
Co-authors Gough Au
2009 Haley ES, Au GG, Carlton BR, Barry RD, Shafren DR, 'Regional administration of oncolytic Echovirus 1 as a novel therapy for the peritoneal dissemination of gastric cancer', Journal of Molecular Medicine, 87 385-399 (2009) [C1]
DOI 10.1007/s00109-008-0433-0
Citations Scopus - 11Web of Science - 9
Co-authors Gough Au
2004 Shafren DR, Au GG, Nguyen T, Barry RD, Hansbro NG, Harvey ES, et al., 'Systemic therapy of malignant human melanoma tumors by a common cold-producing enterovirus, Coxsackievirus A21', Clinical Cancer Research, 10 53-60 (2004) [C1]
DOI 10.1158/1078-0432.CCR-0690-3
Citations Scopus - 70Web of Science - 73
Co-authors Nicole Hansbro, Gough Au
Show 5 more journal articles

Conference (3 outputs)

Year Citation Altmetrics Link
2019 Harvey E, Langton D, Powell H, Gibson P, 'CLINICAL RESPONSE TO MEPOLIZUMAB IN PATIENTS WITH SEVERE EOSINOPHILIC ASTHMA', RESPIROLOGY (2019)
Co-authors Peter Gibson
2018 McDonald VM, Hiles SA, Godbout K, Harvey ES, Marks GB, Hew M, et al., 'Identification of treatable traits in a severe asthma registry: prevalence and exacerbation predictors', EUROPEAN RESPIRATORY JOURNAL, Paris, FRANCE (2018)
DOI 10.1183/13993003.congress-2018.PA5043
Co-authors Vanessa Mcdonald, Sarah Hiles, Peter Gibson, Peter Wark
2017 Wang G, Gibson PG, Wang F, Guo M, Zhang W, Gao P, et al., 'Severe Asthma, Uncontrolled Asthma, And The Use Of Triple Controller Therapy For Asthma In China', AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, Washington, DC (2017)
Co-authors Peter Gibson
Edit

Dr Erin Harvey

Position

Research Assistant
Department of Respiratory & Sleep Medicine
School of Medicine and Public Health
Faculty of Health and Medicine

Contact Details

Email erin.harvey@newcastle.edu.au
Phone (02) 4042 0099
Fax (02) 4042 0046

Office

Building Hunter Medical Research Institute
Location Level 2 West Wing, Hunter Medical Research Institute, Lot 1 Kookaburra Circuit New Lambton Heights 2305

,
Edit